RHUMBLINE ADVISERS

Position in NVS — Novartis AG

CIK 1115418 BOSTON, MA

Position in NVS

as of Jun 30, 2026 · filed Aug 12, 2026 Compact

Position Value

$5,632,986

+$117,795 QoQ

Shares Held

35,943

-0.5% QoQ

Ownership

0.002%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#249

of 1,603 holders

Holding Since

Dec 2020

14 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

RHUMBLINE ADVISERS holds $4,800,494,597 across 17 Drug Manufacturers - General names. NVS ranks #11 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	LLY	ELI LILLY & Co	1,333,307	$1,599,208,548
2	JNJ	Johnson & Johnson	3,780,752	$960,197,585
3	ABBV	AbbVie Inc.	2,733,648	$687,895,182
4	MRK	Merck & Co., Inc.	3,809,518	$489,523,063
5	AMGN	Amgen Inc	904,954	$327,701,942
6	GILD	Gilead Sciences, Inc.	2,051,819	$259,226,812
7	PFE	Pfizer Inc	8,609,603	$207,319,240
8	BMY	Bristol Myers Squibb Co	3,347,347	$192,874,134

14 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$5,632,986	35,943	-0.5%	Shares	Sole	2026-08-12
2026-03-31	$5,515,191	36,106	-0.1%	Shares	Sole	2026-05-12
2025-12-31	$4,982,621	36,140	-2.8%	Shares	Sole	2026-02-13
2025-09-30	$4,765,911	37,164	-4.6%	Shares	Sole	2025-11-06
2025-06-30	$4,713,702	38,953	+0.9%	Shares	Sole	2025-08-12
2025-03-31	$4,303,128	38,600	+11.1%	Shares	Sole	2025-05-29
2024-12-31	$3,381,911	34,754	-14.0%	Shares	Sole	2025-05-29
2024-09-30	$4,645,657	40,390	+6.8%	Shares	Sole	2024-11-12
2024-06-30	$4,025,252	37,810	+1.3%	Shares	Sole	2024-08-01
2024-03-31	$3,609,093	37,311	+7.9%	Shares	Sole	2024-05-09
2023-12-31	$3,491,643	34,581	+1.2%	Shares	Sole	2024-02-08
2023-09-30	$3,481,880	34,183	+16.7%	Shares	Sole	2023-11-09
2023-06-30	$2,955,250	29,286	+713.5%	Shares	Sole	2023-08-08
2020-12-31	$339,948	3,600	—	Shares	Sole	2021-02-10
No filing history on record for this holder in this stock.